anti-CD3/anti-CD19 T-cell engager (SpectraMab)

N/A

Report date: 2026/03/19 16:57:34

Base Information

Drug Nameanti-CD3/anti-CD19 T-cell engager (SpectraMab)

Drug Alias Name43543

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT cell surface glycoprotein CD3 modulators

TargetsB-lymphocyte antigen CD19T cell surface glycoprotein CD3

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesSpectraMab

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSpectraMab

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A